Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 32, 06 March 2024
Open
Access | Article
Vaccine innovations and potential targets of breast cancer
* Author to whom correspondence should be addressed.
Abstract
Breast cancer is a concerning worldwide disease that is fatal. Although treatments had been developed over the past, prevention was still on the road of discovery. There are still no vaccines that have been approved for treatment or prevention by the year 2023. In this review, the feasibility of two types of vaccines and potential targets was assessed, with links to future paths of breast cancer vaccine investigations. Messenger RNA (mRNA) vaccine and a tissue-specific self-protein -Lactalbumin vaccination are two types of potential vaccines facing towards breast cancer with different pathogenesis of overexpression in HER2 or the -Lactalbumin. Sufficient research had been done on the mRNA vaccines showing HER2 as a potential target that shows the most positive result in vaccine clinical trials. Research on -Lactalbumin were less compared to mRNA vaccines, but the results showed that -Lactalbumin was immunogenic enough to induce effective tumor immunity in healthy adult women.
Keywords
mRNA vaccination, -Lactalbumin, breast cancer, immunoprevention, immunotherapy
References
1. World Health Organization. “Breast Cancer.” Www.who.int, World Health Organization, 12 July 2023, www.who.int/news-room/fact-sheets/detail/breast-cancer.
2. Tay, Ban Qi, et al. “Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions.” Vaccines, vol. 9, no. 5, 1 May 2021, p. 535, www.mdpi.com/2076-393X/9/5/535, https://doi.org/10.3390/vaccines9050535.
3. “CTG Labs - NCBI.” Clinicaltrials.gov, 30 Mar. 2020, clinicaltrials.gov/study/NCT00524277. Accessed 1 Nov. 2023.
4. Watson, Stephanie. “Vaccine Treatment for Metastatic Breast Cancer.” WebMD, www.webmd.com/breast-cancer/metastatic-breast-cancer-vaccine-treatment. Accessed 1 Nov. 2023.
5. Jiang, Xiao-Ting, and Qiang Liu. MRNA Vaccination in Breast Cancer: Current Progress and Future Direction. 26 Apr. 2023, https://doi.org/10.1007/s00432-023-04805-z. Accessed 27 June 2023.
6. McNamara, Megan A., et al. “RNA-Based Vaccines in Cancer Immunotherapy.” Journal of Immunology Research, vol. 2015, 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4668311/, https://doi.org/10.1155/2015/794528.
7. Gote, Vrinda, et al. “A Comprehensive Review of MRNA Vaccines.” International Journal of Molecular Sciences, vol. 24, no. 3, 31 Jan. 2023, p. 2700, https://doi.org/10.3390/ ijms24032700.
8. Crosby, Erika J., et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 25, no. 9, 1 May 2019, pp. 2725–2736, pubmed.ncbi.nlm.nih.gov/30635338, https://doi.org/10.1158/1078-0432.CCR-18-3102. Accessed 26 May 2021.
9. Met, Ozcan, et al. “High Immunogenic Potential of P53 MRNA-Transfected Dendritic Cells in Patients with Primary Breast Cancer.” Breast Cancer Research and Treatment, vol. 125, no. 2, 1 Jan. 2011, pp. 395–406, pubmed.ncbi.nlm.nih.gov/20336365/, https://doi.org/10.1007/ s10549-010-0844-9. Accessed 1 Nov. 2023.
10. Liu, Lina, et al. “Combination Immunotherapy of MUC1 MRNA Nano-Vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.” Molecular Therapy, vol. 26, no. 1, Jan. 2018, pp. 45–55, https://doi.org/10.1016/j.ymthe.2017.10.020.
11. Lyerly, H. Kim . “A Phase I Study to Evaluate the Antitumor Activity and Safety of AVX901.” Clinicaltrials.gov, clinicaltrials.gov/study/NCT01526473. Accessed 1 Nov. 2023.
12. Lundstrom, Kenneth. “Self-Amplifying RNA Viruses as RNA Vaccines.” International Journal of Molecular Sciences, vol. 21, no. 14, 20 July 2020, p. 5130, https://doi.org/10.3390/ ijms21145130.
13. Tuohy, Vincent, et al. “Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.” Cancers, vol. 8, no. 6, 16 June 2016, p. 56, https://doi.org/10.3390/cancers8060056. Accessed 6 July 2020.
14. Rhodes, Daniel R, et al. “ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform.” Neoplasia (New York, N.Y.), vol. 6, no. 1, 1 Jan. 2004, pp. 1–6, www.ncbi.nlm.nih.gov/pmc/articles/PMC1635162/.
15. Tomczak, Katarzyna, et al. “Review the Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge.” Współczesna Onkologia, vol. 1A, 2015, pp. 68–77, www.ncbi.nlm.nih. gov/pmc/articles/PMC4322527/, https://doi.org/10.5114/wo.2014.47136.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-321-0
- ISBN (Online)
- 978-1-83558-322-7
- Published Date
- 06 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/32/20240796
- Copyright
- 06 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited